Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6962 USD | +0.19% | +0.90% | -15.27% |
Mar. 18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Camac Partners Provides Information to Shareholders | CI |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.27% | 25.34M | - | D+ | |
+2.73% | 108B | B+ | ||
+9.59% | 103B | B+ | ||
+6.58% | 23.48B | B | ||
-12.59% | 21.93B | B+ | ||
-3.29% | 19.68B | A- | ||
-35.36% | 18.37B | A- | ||
-13.29% | 16.33B | B | ||
+4.68% | 13.72B | C+ | ||
+34.25% | 12.15B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Forte Biosciences, Inc. - Nasdaq
- Ratings Forte Biosciences, Inc.